Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America..
To investigate if the AY.4.2 sublineage of the SARS-CoV-2 delta variant is associated with hospitalization and mortality risks that differ from non-AY.4.2 delta risks, we performed a retrospective cohort study of sequencing-confirmed COVID-19 cases in England based on linkage of routine health care datasets. Using stratified Cox regression, we estimated adjusted hazard ratios (aHR) of hospital admission (aHR = 0.85; 95% confidence interval [CI], .77-.94), hospital admission or emergency care attendance (aHR = 0.87; 95% CI, .81-.94), and COVID-19 mortality (aHR = 0.85; 95% CI, .71-1.03). The results indicate that the risks of hospitalization and mortality are similar or lower for AY.4.2 compared to cases with other delta sublineages.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:226 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 226(2022), 5 vom: 13. Sept., Seite 808-811 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nyberg, Tommy [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AY.4.2 |
|---|
| Anmerkungen: |
Date Completed 15.09.2022 Date Revised 25.09.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiac063 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337160392 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337160392 | ||
| 003 | DE-627 | ||
| 005 | 20231225233758.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiac063 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1123.xml |
| 035 | |a (DE-627)NLM337160392 | ||
| 035 | |a (NLM)35184201 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nyberg, Tommy |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.09.2022 | ||
| 500 | |a Date Revised 25.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. | ||
| 520 | |a To investigate if the AY.4.2 sublineage of the SARS-CoV-2 delta variant is associated with hospitalization and mortality risks that differ from non-AY.4.2 delta risks, we performed a retrospective cohort study of sequencing-confirmed COVID-19 cases in England based on linkage of routine health care datasets. Using stratified Cox regression, we estimated adjusted hazard ratios (aHR) of hospital admission (aHR = 0.85; 95% confidence interval [CI], .77-.94), hospital admission or emergency care attendance (aHR = 0.87; 95% CI, .81-.94), and COVID-19 mortality (aHR = 0.85; 95% CI, .71-1.03). The results indicate that the risks of hospitalization and mortality are similar or lower for AY.4.2 compared to cases with other delta sublineages | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a AY.4.2 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a VUI-21OCT-01 | |
| 650 | 4 | |a hospitalization | |
| 650 | 4 | |a mortality | |
| 700 | 1 | |a Harman, Katie |e verfasserin |4 aut | |
| 700 | 1 | |a Zaidi, Asad |e verfasserin |4 aut | |
| 700 | 1 | |a Seaman, Shaun R |e verfasserin |4 aut | |
| 700 | 1 | |a Andrews, Nick |e verfasserin |4 aut | |
| 700 | 1 | |a Nash, Sophie G |e verfasserin |4 aut | |
| 700 | 1 | |a Charlett, Andre |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez Bernal, Jamie |e verfasserin |4 aut | |
| 700 | 1 | |a Myers, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Groves, Natalie |e verfasserin |4 aut | |
| 700 | 1 | |a Gallagher, Eileen |e verfasserin |4 aut | |
| 700 | 1 | |a Gharbia, Saheer |e verfasserin |4 aut | |
| 700 | 1 | |a Chand, Meera |e verfasserin |4 aut | |
| 700 | 1 | |a Thelwall, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a De Angelis, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Dabrera, Gavin |e verfasserin |4 aut | |
| 700 | 1 | |a Presanis, Anne M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 226(2022), 5 vom: 13. Sept., Seite 808-811 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:226 |g year:2022 |g number:5 |g day:13 |g month:09 |g pages:808-811 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiac063 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 226 |j 2022 |e 5 |b 13 |c 09 |h 808-811 | ||